A cost‐effectiveness analysis of stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the management of stage 1 non‐small‐cell lung cancer: Results from the TROG 09.02 CHISEL study
Compared to CRT, SABR is a cost-effective treatment for early-stage NSCLC as the estimated upfront treatment cost and the cost of subsequent care are lower for SABR for comparable mean QALYs. Assessment of the lifetime QALYs and projections of cost estimation will provide a better indication of the long-term cost-effectiveness of SABR.
Authors
- Hien V. Le (ORCID: https://orcid.org/0000-0002-1527-5889)
- David Ball (ORCID: https://orcid.org/0000-0002-0491-6919)
- A. Byrne (ORCID: https://orcid.org/0009-0002-3449-9148)
- Richard De Abreu Lourenço (ORCID: https://orcid.org/0000-0002-5978-8774)
- Ramkumar Govindaraj (ORCID: https://orcid.org/0000-0002-7229-7179)
Institutions
- University of Technology Sydney (AU)
- The University of Melbourne (AU)
- University of South Australia (AU)
- Peter MacCallum Cancer Centre (AU)
- Royal Hobart Hospital (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Journal of Medical Imaging and Radiation Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1111/1754-9485.13755
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42